Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > COMMENTARY
COMMENTARY
- COMMENTARY New Promotion Code to Go into Effect Next January
October 30, 2006
- 70% of People 40 Years or Older Have Pain in Joints, Lower Back: Survey by Stryker
October 23, 2006
- Surveys by JMA, FTC Provide Evidence for Discussions on Generics
October 16, 2006
- COMMENTARY／Original and Generic Makers Should Cooperate for Stable Supply
September 11, 2006
- COMMENTARY Government Increases Efforts to Promote Clinical Research
September 4, 2006
- TOPICS 2 articles
August 28, 2006
- COMMENTARY／Government Increases Efforts to Promote Clinical Research
August 28, 2006
- Blockbuster Sales of International Majors in 2005: Rankings of Companies and Therapeutic Areas Keiji Nakamura, Ph.D. Pharma Forum Institute, Kamakura, Japan http://www.pharma-fi.com/index.html
August 21, 2006
- COMMENTARY 3 articles
August 7, 2006
- 5 Major New Drugs Affected by Listing of 1st Generics
July 31, 2006
- COMMENTARY：New Clinical Trial Stimulation Plan to Go in Tandem with New Industry Vision
July 17, 2006
- COMMENTARY Social Security Spending to Be Cut by \1.6 Tril.↓
July 10, 2006
- COMMENTARY Amended PAL to Remake Retail Industry
July 10, 2006
- Generic Drug Market Sees New Era of Competition 5 articles
July 3, 2006
- Drug Industry Reorganization in the Future ―No More Argument, Unexpected Leaders?―
June 19, 2006
- COMMENTARY 3 articles
June 19, 2006
- Predicting the Future Market for Smoking Cessation Aids: Will OTC Products Continue to Outsell Ethical Products?
June 5, 2006
- Major Domestic Companies Invest More Than Ever in R&D
May 29, 2006
- Incident in PI Trial in UK 5 articles
May 8, 2006
- COMMENTARY 3 articles
April 24, 2006
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…